Expert Opinion on Biological Therapy最新文献_第3页

Clinical management and innovation in fracture non-union. 骨折不愈合的临床管理与创新。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1080/14712598.2024.2391491

C Siverino, W-J Metsemakers, R Sutter, E Della Bella, M Morgenstern, J Barcik, M Ernst, M D'Este, A Joeris, M Chittò, P Schwarzenberg, M Stoddart, N Vanvelk, G Richards, E Wehrle, F Weisemann, S Zeiter, C Zalavras, P Varga, T F Moriarty

{"title":"Clinical management and innovation in fracture non-union.","authors":"C Siverino, W-J Metsemakers, R Sutter, E Della Bella, M Morgenstern, J Barcik, M Ernst, M D'Este, A Joeris, M Chittò, P Schwarzenberg, M Stoddart, N Vanvelk, G Richards, E Wehrle, F Weisemann, S Zeiter, C Zalavras, P Varga, T F Moriarty","doi":"10.1080/14712598.2024.2391491","DOIUrl":"10.1080/14712598.2024.2391491","url":null,"abstract":"Introduction: With the introduction and continuous improvement in operative fracture fixation, even the most severe bone fractures can be treated with a high rate of successful healing. However, healing complications can occur and when healing fails over prolonged time, the outcome is termed a fracture non-union. Non-union is generally believed to develop due to inadequate fixation, underlying host-related factors, or infection. Despite the advancements in fracture fixation and infection management, there is still a clear need for earlier diagnosis, improved prediction of healing outcomes and innovation in the treatment of non-union.Areas covered: This review provides a detailed description of non-union from a clinical perspective, including the state of the art in diagnosis, treatment, and currently available biomaterials and orthobiologics.Subsequently, recent translational development from the biological, mechanical, and infection research fields are presented, including the latest in smart implants, osteoinductive materials, and in silico modeling.Expert opinion: The first challenge for future innovations is to refine and to identify new clinical factors for the proper definition, diagnosis, and treatment of non-union. However, integration of in vitro, in vivo, and in silico research will enable a comprehensive understanding of non-union causes and correlations, leading to the development of more effective treatments.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process. 美国食品和药物管理局批准用于治疗杜氏肌营养不良症的 delandistrogene moxeparvovec-rokl：对证据和监管程序的批判性审查。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-20 DOI: 10.1080/14712598.2024.2394477

Mehul Bhattacharyya, Larry E Miller, Anna L Miller, Ruemon Bhattacharyya

引用次数: 0

The future of aptamers in cancer diagnosis, prognosis and treatment. 适配体在癌症诊断、预后和治疗中的未来。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-03 DOI: 10.1080/14712598.2024.2399148

Jazmine Arévalo, Adrian Gabriel Torres

引用次数: 0

IL-17 inhibitors in axial spondyloarthritis. An overview. 轴性脊柱关节炎中的 IL-17 抑制剂。综述。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.1080/14712598.2024.2394472

Eric Toussirot, Renaud Felten

{"title":"IL-17 inhibitors in axial spondyloarthritis. An overview.","authors":"Eric Toussirot, Renaud Felten","doi":"10.1080/14712598.2024.2394472","DOIUrl":"10.1080/14712598.2024.2394472","url":null,"abstract":"Introduction: The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spondyloarthritis (axSpA).Areas covered: This literature review provides an update on the role of IL-17 in the pathogenesis of axSpA, efficacy and safety from clinical trials and real-life studies on the use of IL17i in axSpA. We also review the impact of extra-musculoskeletal manifestations on the decision to treat with IL17i and the efficacy of IL17i on structural progression.Expert opinion: There are still some unanswered questions concerning the use of IL-17i in axSpA in clinical practice such as their respective place in the management of axSpA compared to TNFα inhibitors (TNFi). Their main differences rely on their specific efficacy in extra-articular manifestations such as psoriasis, uveitis, and inflammatory bowel diseases leading to the choice of the best treatment in a given patient. Regarding their real impact on structural progression, the rate of progression under IL-17i appears to be low and presumably similar to TNFi. One final question is the advantage of blocking the two IL-17 isoforms A and F compared to the single inhibition of IL-17A.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia. 对 exagamglogene autotemcel 治疗镰状细胞病和输血依赖型β-地中海贫血症的评估。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/14712598.2024.2399134

Rupert Handgretinger, Markus Mezger

{"title":"An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.","authors":"Rupert Handgretinger, Markus Mezger","doi":"10.1080/14712598.2024.2399134","DOIUrl":"10.1080/14712598.2024.2399134","url":null,"abstract":"Introduction: Sickle cell disease is the most common hereditary hemoglobinopathy followed by beta-thalassemia. Until recently, allogeneic stem cell transplantation was the only curative approach. Based on the Crispr-Cas9-technology enabling targeting specific genes of interest, fetal hemoglobin which is normally shut-off after birth can be switched on and sufficient levels can alleviate symptoms in sickle cell disease and avoid transfusions in beta-thalassemia. Two first-in-human clinical studies in sickle cell disease and beta-thalassemia aiming to increase the level of fetal hemoglobin by using Crispr-Cas9 to modify autologous hematopoietic stem cells in patients aged 12-35 years have proved safety and efficacy and have shown promising clinical outcomes.Areas covered: The paper summarizes the outcome of the results of the two recently published clinical studies and compares them with the other available curative approaches.Expert opinion: Based on the currently available safety and efficacy data of the two published clinical results on gene therapy with Crispr-Cas9 modified autologous stem cells (exagamglogene autotemcel), it can be anticipated that this approach will add significantly to the therapeutic options for patients with sickle cell disease and beta-thalassemia and can be considered for all patients above 12 years of age independent of a suitable allogeneic stem cell donor.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1080/14712598.2024.2390778

引用次数: 0

T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement. 多发性骨髓瘤的 T 细胞重定向双特异性抗体治疗：T 细胞持续参与的现有知识和未来策略。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-09-01 DOI: 10.1080/14712598.2024.2397436

Marise R Heerma van Voss, Remco J Molenaar, Charlotte L B M Korst, Imke H Bartelink, Serena R Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T Kuipers, Niels W C J van de Donk

{"title":"T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.","authors":"Marise R Heerma van Voss, Remco J Molenaar, Charlotte L B M Korst, Imke H Bartelink, Serena R Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T Kuipers, Niels W C J van de Donk","doi":"10.1080/14712598.2024.2397436","DOIUrl":"10.1080/14712598.2024.2397436","url":null,"abstract":"Introduction: T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein - coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the treatment of patients with relapsed or refractory MM.Areas covered: This review discusses the pharmacokinetic properties, efficacy, and safety profile of T-cell redirecting BsAbs in MM, with a special focus on their optimal dosing schedule, resistance mechanisms and future strategies to enhance efficacy, reduce toxicity, and maximize duration of response.Expert opinion: To further improve the efficacy of BsAbs, ongoing studies are investigating whether combination therapy can enhance depth and duration of response. An important open question is also to what extent response to BsAbs can be improved when these agents are used in earlier lines of therapy. In addition, more evidence is needed on rational de-intensification strategies of BsAb dosing upon achieving a sufficient response, and if (temporary) treatment cessation is possible in patients who have achieved a deep remission (e.g. complete response or minimal residual disease-negative status).","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perispinal etanercept stroke trial design: PESTO and beyond. 围皮层依那西普中风试验设计：PESTO 及其他

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-23 DOI: 10.1080/14712598.2024.2390636

Edward Tobinick, Danielle Ucci, Kirsten Bermudo, Samantha Asseraf

{"title":"Perispinal etanercept stroke trial design: PESTO and beyond.","authors":"Edward Tobinick, Danielle Ucci, Kirsten Bermudo, Samantha Asseraf","doi":"10.1080/14712598.2024.2390636","DOIUrl":"https://doi.org/10.1080/14712598.2024.2390636","url":null,"abstract":"Introduction: Perispinal etanercept (PSE) is an innovative treatment designed to improve stroke recovery by addressing chronic post-stroke neuroinflammation. Basic science evidence, randomized clinical trial (RCT) evidence and 14 years of favorable clinical experience support the use of PSE to treat chronic stroke. This article provides guidance for the design of future PSE RCTs in accordance with current FDA recommendations.Areas covered: Scientific background and essential elements of PSE RCT design.Expert opinion: Intimate familiarity with PSE, its novel method of drug delivery, and the characteristics of ideal enriched study populations are necessary for those designing future PSE stroke trials. The design elements needed to enable a PSE RCT to generate valid results include a suitable research question; a homogeneous study population selected using a prospective enrichment strategy; a primary outcome measure responsive to the neurological improvements that result from PSE; trialists with expertise in perispinal delivery; optimal etanercept dosing; and steps taken to minimize the number of placebo responders. RCTs failing to incorporate these elements, such as the PESTO trial, are incapable of reaching reliable conclusions regarding PSE efficacy. SF-36 has not been validated in PSE trials and is unsuitable for use as a primary outcome measure in PSE RCTs.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1080/14712598.2024.2388405

引用次数: 0

Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer. 复发性和晚期转移性宫颈癌的新兴生物疗法综述。

IF 3.6 3区医学

Expert Opinion on Biological Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-29 DOI: 10.1080/14712598.2024.2373320

Virginia E Fontenot, Alex Francoeur, Krishnansu S Tewari

引用次数: 0